Advances in single-entity inhaled corticosteroid therapy

Allergy and Asthma Proceedings

Volumn 28, Issue 2, 2007, Pages 125-135

  Tayab, Zia R ^a   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Asthma; Efficacy; Inhaled corticosteroids; Pharmacodynamics; Pharmacokinetics; Pulmonary deposition; Pulmonary selectivity; Safety

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; PRODRUG; STEROID RECEPTOR;

ASTHMA; BIOAVAILABILITY; CHEMISTRY; CONFERENCE PAPER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG THERAPY; EQUIPMENT DESIGN; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; NEBULIZER; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROTEIN BINDING; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; EQUIPMENT DESIGN; HUMANS; METABOLIC CLEARANCE RATE; NEBULIZERS AND VAPORIZERS; PRODRUGS; PROTEIN BINDING; RECEPTORS, STEROID; TISSUE DISTRIBUTION;

EID: 34248379654     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.2981     Document Type: Conference Paper

References (70)

1. World Health Organization (WHO). WHO fact sheet no 206. WHO, Geneva, 2002.
2. National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO). Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. Workshop Report. National Institutes of Health, Bethesda, MD, 2004.
3. 2-agonists on asthma pathophysiology: A review of the evidence. Drugs 63(suppl 2):35-51, 2003.
4. Williams DM. Clinical considerations in the use of inhaled corticosteroids for asthma. Pharmacotherapy 21:385-485, 2001
5. Toogood JH. Side effects of inhaled corticosteroids. J Allergy Clin Immunol 102:705-713, 1998.
6. Lipworth BJ, and Jackson CM. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf 23: 11-33, 2000.
7. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47, 2004.
8. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 91:326-334, quiz 334-335, 404, 2003.
9. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 1:264-268, 2004.
10. Ito K, Chung KF, and Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117:522-543, 2006.
11. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75:433-438, 1986.
12. Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sci 77:340-346, 1988.
13. Hochhaus G, Mollmann H, Derendorf H, and Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37:881-892, 1997.
14. Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 156:744-751, 1997.
15. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 40:1227-1236, 2000.
16. Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 53:459-467, 1998.
17. Nave R, Bethke TD, van Marie SP, and Zech K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43:479-486, 2004.
18. Thorsson L, Dahlstrom K, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43:155-161, 1997.
19. Schleimer R, O'Byrne P, Szefler S, and Brattsand R. Prospects for developing inhaled steroids with extrahepatic metabolism: Soft steroids. New York: Marcel Dekker, 273-281, 2002.
20. Cooray HC, Shahi S, Cahn AP, et al. Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531:25-33, 2006.
21. Karssen AM, Meijer OC, van der Sandt IC, et al. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175:251-260, 2002.
22. Meijer OC, de Lange EC, Breimer DD, et al. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139: 1789-1793, 1998.
23. Meijer OC, Karssen AM, and de Kloet ER. Cell- and tissue-specific effects of corticosteroids in relation to glucocorticoid resistance: examples from the brain. J Endocrinol 178:13-18, 2003.
24. Arya V, Issar M, Wang Y, et al. Brain permeability of inhaled corticosteroids. J Pharm Pharmacol 57:1159-1167, 2005.
25. Arya V, Demarco VG, Issar M, and Hochhaus G. Contrary to adult, neonatal rats show pronounced brain uptake of corticosteroids. Drug Metab Dispos 34:939-942, 2006.
26. Ceckova-Novotna M, Pavek P, and Staud F. P-glycoprotein in the placenta: Expression, localization, regulation, and function. Reprod Toxicol 22:400-410, 2006.
27. Sun M, Kingdom J, Baczyk D, et al. Expression of the multidrug resistance p-glycoprotein, (abcb1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602-609, 2005.
28. Young AM, Allen CE, and Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 55:125-132, 2003.
29. Murphy VE, Fittock RJ, Zarzycki PK, et al. Metabolism of synthetic steroids by the human placenta. Placenta 28:39-46, 2006.
30. Lechapt-Zalcman E, Hurbain I, Lacave R, et al. MDRl-Pgp 170 expression in human bronchus. Eur Respir J 10:1837-1843, 1997.
31. van der Deen M, de Vries EG, Timens W, et al. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6:59, 2005.
32. Toogood JH. An appraisal of the influence of dose frequency on the antiasthmatic activity of inhaled corticosteroids. Ann Allergy 55:2-4, 1985.
33. Harrison TW, and Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58:258-260, 2003.
34. Harrison TW, Wisniewski A, Honour J, and Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 56:186-191, 2001
35. Edsbacker S, and Brattsand R. Budesonide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 88: 609-616, 2002.
36. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45:146-152, 2005.
37. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(suppl A):22-28, 1997
38. Derendorf H, Hochhaus G, Krishnaswami S, et al. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Pharmazie 55:223-227, 2000.
39. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43: 365-378, 2003.
40. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12:201-209, 2005.
41. Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc 1:269-274, 2004.
42. Winkler J, Hochhaus G, and Derendorf H. How the lung handles drugs: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 1:356-363, 2004.
43. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a. selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101:227-232, 2004.
44. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 17:860-869, 2003.
45. Kym PR, Kort ME, Coghlan MJ, et al. Nonsteroidal selective glucocorticoid modulators: The effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4- f]quinolines. J Med Chem 46:1016-1030, 2003.
46. Lin CW, Nakane M, Stashko M, et al. Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol 62:297-303, 2002.
47. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11: 1245-1255, 1997.
48. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166:1975-1982, 2001.
49. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: Patient compliance, devices, and inhalation technique. Chest 117:542-550, 2000.
50. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: Intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 25:2276-2281, 1997.
51. Geller DE. New liquid aerosol generation devices: Systems that force pressurized liquids through nozzles. Respir Care 47:1392-1404, discussion 1404-1405, 2002.
52. Zimlich WC, Ding J, Busick D, et al. Development of multiple clinical and commercial applications using Mystic inhalation technologies. In Respiratory Drug Delivery VIII, Vol. 2. Dalby RN, Byron PR, Farr SJ, and Peart J (Eds). Tucson, AZ: Serentec Press, 363-366, 2002.
53. Shaw RJ. Inhaled corticosteroids for adult asthma: Impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir Med 93:149-160, 1999.
54. James AL. Peripheral airways in asthma. Curr Allergy Asthma Rep 2:166-174, 2002.
55. Pitcairn G, Reader S, Pavia D, and Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 18:264-272, 2005.
56. Newman S, Salmon A, Nave R, and Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100:375-384, 2006.
57. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study. Lancet 356:556-561, 2000.
58. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics, and metabolism following intravenous, oral, intranasal, and inhaled administration in man. Br J Clin Pharmacol 51:400-409, 2001.
59. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:5440-3446, 1998.
60. Derendorf H, Hochhaus G, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:302-305, 1995.
61. Hochhaus G, Sahasranaman S, Derendorf H, and Moellmann H. Intranasal glucocorticoid delivery: Competition between local and systemic effects. Sci Tech Inf Pharm: Pharmaceut Sci 12:23-31, 2002.
62. Mollmann H, Derendorf H, Barth J, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 37:893-903, 1997.
63. Onrust SV, and Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 56:725-745, 1998.
64. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 36:938-941, 1996.
65. Sharpe M, and Jarvis B. Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma. Drugs 61:1325-1350, 2001.
66. Smith CL, and Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48:956-960, 1998.
67. Wuerthwein G, Rehder S, and Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharmazeutische Zeitung Wissenschaft 137:161-167, 1992.
68. Leach CL, Davidson PJ, Hasselquist BE, and Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: A cross-over study in healthy volunteers. Chest 122:510-516, 2002.
69. Mackie AE, Falcoz C, McDowall JE, et al. Pharmacokinetics of fluticasone propionate inhaled from the diskhaler and the Diskus powder devices in healthy subjects. Br J Pharmacol. 120 (suppl):P249, 1997.
70. Thorsson L, Edsbacker S, and Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 7:1839-1844, 1994.